GTCB Math -
Dew - thanks for the Scientific American article. In the article, Cox estimates that total Atryn sales could be as high as $700 million annually if you include the full potential array of treatments (coronary bypass, burns, etc.)
If you assumed that they achieved:
1) Half of that revenue estimate - $350 million
2) At a 15% after-tax profit
3) With a 40 multiple
4) With 60 million shares outstanding (after further dilution)
The above equates to $35/share (it's now at $1.37)
Assuming I haven't screwed up the math, if they make this work, I'll be a very wealthy man. If they don't, it will be retirement in that Winnebago..!
Seriously, at this point it's a crap shoot. I'm in for the ride though as the upside could be significant.
